RUA Life Sciences (LSE:RUA) EBIT: £-0.24 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:RUA RUA Life Sciences PLC LSE:RUA
47 GF Score
Price £0.24
GF Value £0.17
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is RUA Life Sciences EBIT?

RUA Life Sciences LSE:RUA +4.35% 47 EBIT is £-0.24 Mil as of Mar. 2026. GuruFocus rates LSE:RUA with a GF Score™ of 47/100 and a GF Value™ of £0.17 (Significantly Overvalued). The stock has 5 warning signs investors should review.

RUA Life Sciences's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was £-0.24 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was £-0.24 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. RUA Life Sciences's annualized ROC % for the quarter that ended in Mar. 2026 was -8.61%. RUA Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -12.11%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. RUA Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1.83%.

RUA Life Sciences  (LSE:RUA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

RUA Life Sciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-0.484 * ( 1 - 0% )/( (5.398 + 5.839)/ 2 )
=-0.484/5.6185
=-8.61 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.255 - 0.29 - ( 3.567 - max(0, 1.102 - 5.413+3.567))
=5.398

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.598 - 0.394 - ( 2.365 - max(0, 0.86 - 5.094+2.365))
=5.839

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

RUA Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.484/( ( (3.166 + max(0.561, 0)) + (2.895 + max(1.371, 0)) )/ 2 )
=-0.484/( ( 3.727 + 4.266 )/ 2 )
=-0.484/3.9965
=-12.11 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.519 + 0.754 + 0) - (0.29 + 0 + 0.422)
=0.561

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.963 + 0.96 + 0.142) - (0.394 + 0 + 0.3)
=1.371

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

RUA Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-0.242/13.219
=-1.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RUA Life Sciences EBIT Related Terms

RUA Life Sciences EBIT Historical Data

* Premium members only.

The historical data trend for RUA Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RUA Life Sciences EBIT Chart

RUA Life Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.90 -1.56 -2.35 -2.31 -1.95

RUA Life Sciences Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.36 -0.59 0.67 -0.69 -0.24

LSE:RUA vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, RUA Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RUA Life Sciences EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's EV-to-EBIT falls into.


LSE:RUA
47GF Score
RUA Life Sciences PLC LSE:RUA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RUA Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of £-0.24 Mil mean?
RUA Life Sciences (LSE:RUA) has a EBIT of £-0.24 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on RUA Life Sciences.
Is RUA Life Sciences' EBIT too high?
RUA Life Sciences' current EBIT is £-0.24 Mil. Overall, RUA Life Sciences has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' EBIT compare to ABT and SYK?
RUA Life Sciences' EBIT of £-0.24 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on RUA Life Sciences. RUA Life Sciences's current EBIT is £-0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (LSE:RUA) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.17, compared to a current price of £0.24 — trading 41.2% above its estimated fair value. The current EBIT is £-0.24 Mil. RUA Life Sciences' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For RUA Life Sciences (LSE:RUA), the current EBIT is £-0.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RUA Life Sciences (LSE:RUA) Overvalued in 2026?

Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued. The current stock price of £0.24 is trading 41.2% above its estimated GF Value™ of £0.17. GuruFocus considers RUA Life Sciences to be Significantly Overvalued.

Key valuation signals for LSE:RUA:

  • EBIT: £-0.24 Mil
  • GF Value™: £0.17 vs. price of £0.24 (41.2% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the LSE:RUA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RUA Life Sciences Business Description

Other Exchanges AOHA:Germany
Address 2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
47GF Score

Get the complete analysis for LSE:RUA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.24
Price
£0.17
GF Value